Alembic Pharmaceuticals Secures USFDA Approval for Generic Allergy Eye Drops, Expands US Portfolio

Indian pharmaceutical manufacturer Alembic Pharmaceuticals Limited has received final approval from the United States Food and Drug Administration (USFDA) for its generic Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, strengthening the company’s portfolio of ophthalmic medicines in the regulated American pharmaceutical market. The approval covers an over-the-counter (OTC) formulation intended to provide temporary relief from itchy eyes caused by environmental allergens, including pollen, ragweed, grass, animal hair and dander.

In a regulatory disclosure submitted to the Indian stock exchanges on November 4, Alembic confirmed that the USFDA had granted final approval for its Abbreviated New Drug Application (ANDA). The approved formulation is therapeutically equivalent to Pataday Once Daily Relief 0.7%, the reference product marketed by Alcon Laboratories. The development represents another regulatory milestone for the Vadodara-headquartered pharmaceutical company as it continues expanding its presence in the United States through generic medicines and specialised formulations.

The product was developed in collaboration with Orbicular Pharmaceutical Technologies Private Limited, an Indian pharmaceutical research and development company specialising in complex drug delivery technologies. According to market research data from IQVIA cited by Alembic, the US market for Olopatadine Hydrochloride Ophthalmic Solution 0.7% was valued at approximately USD 20 million during the twelve months ending September 2026.

USFDA Approval Strengthens Alembic’s Ophthalmic Portfolio

The latest approval allows Alembic to proceed with commercialisation of its generic olopatadine ophthalmic formulation in the United States, subject to applicable regulatory and distribution requirements.

Olopatadine belongs to a class of medicines known as antihistamines and is used to relieve symptoms associated with allergic conjunctivitis. The medicine works by blocking the action of histamine, a substance released by the body during allergic reactions that can cause itching, redness and other symptoms affecting the eyes.

The approved 0.7% ophthalmic solution is intended for once-daily use in accordance with its product labelling. Its over-the-counter status allows consumers in the United States to obtain the medicine without a prescription, providing an established treatment option for temporary relief from allergy-related eye itching.

The formulation addresses symptoms caused by common environmental allergens, including seasonal pollen and grass exposure, as well as allergens associated with animal hair and dander. These triggers can cause discomfort among individuals experiencing seasonal or perennial ocular allergies.

Alembic’s generic product is therapeutically equivalent to the reference-listed medicine, meaning it has satisfied the applicable regulatory requirements for approval as a generic alternative.

Approval Follows Earlier Tentative Regulatory Clearance

The November 2026 final approval follows an earlier regulatory milestone achieved by Alembic in December 2024, when the company received tentative USFDA approval for the same 0.7% olopatadine ophthalmic solution.

Tentative approval indicates that a generic drug application has satisfied the relevant scientific and regulatory requirements for approval but cannot yet receive final approval because of applicable patent or exclusivity restrictions.

The transition to final approval represents an important step in the regulatory development of the product, enabling Alembic to pursue commercial distribution in the United States.

The development also highlights the considerable regulatory work involved in bringing generic ophthalmic formulations to market. Such products must satisfy stringent standards relating to pharmaceutical quality, manufacturing consistency, formulation performance and regulatory compliance.

Indian Pharmaceutical Collaboration Supports Generic Drug Development

Alembic developed the approved olopatadine formulation in collaboration with Orbicular Pharmaceutical Technologies Private Limited.

The partnership demonstrates the contribution of specialised Indian pharmaceutical research companies to the development of medicines intended for highly regulated international markets.

Ophthalmic formulations require careful control of several pharmaceutical parameters, including drug concentration, sterility, formulation stability and compatibility with ocular tissues. Manufacturers must demonstrate that their products meet the relevant quality and regulatory requirements before receiving approval for commercial distribution.

The development of generic ophthalmic medicines therefore involves expertise in formulation science, analytical testing, pharmaceutical manufacturing and regulatory documentation.

Collaborations between established pharmaceutical manufacturers and specialised research organisations allow companies to combine their manufacturing and commercial capabilities with focused expertise in drug formulation and development.

For India’s pharmaceutical industry, such arrangements contribute to the growth of domestic capabilities in complex generic medicines and advanced drug delivery systems.

US Market for Olopatadine Formulation Estimated at USD 20 Million

According to IQVIA market data cited in Alembic’s announcement, the US market for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, was valued at approximately USD 20 million during the twelve months ending September 2026.

The market estimate provides an indication of the existing commercial demand for this particular formulation within the American ophthalmic medicines sector.

The introduction of additional generic alternatives can increase competition in established pharmaceutical categories and provide consumers with more treatment options.

For Alembic, the approval creates an opportunity to participate in the US market for over-the-counter allergy eye drops. Actual commercial sales will depend on product launch arrangements, distribution, market competition and consumer demand.

The development is consistent with the company’s broader strategy of expanding its presence in regulated pharmaceutical markets through a diversified portfolio of generic medicines.

Alembic’s Cumulative USFDA Approvals Reach 248

With the latest regulatory clearance, Alembic Pharmaceuticals has received a cumulative total of 248 ANDA approvals from the USFDA, comprising 229 final approvals and 19 tentative approvals.

The expanding approval portfolio reflects the company’s sustained involvement in developing generic medicines for the United States, one of the world’s largest pharmaceutical markets.

ANDA approvals are particularly important for generic pharmaceutical manufacturers because they establish the regulatory basis for introducing medicines that are equivalent to previously approved reference products.

The approval process involves the submission of comprehensive information covering pharmaceutical formulation, manufacturing controls, product quality and applicable evidence demonstrating equivalence to the reference medicine.

Alembic’s portfolio spans multiple therapeutic categories and dosage forms, supported by its pharmaceutical research, development and manufacturing operations in India.

The growing number of approvals also demonstrates the importance of regulatory expertise and sustained investment in research and development for Indian companies seeking to expand their international pharmaceutical businesses.

Indian Pharmaceutical Companies Expand Their Presence in Regulated Markets

The latest approval highlights the continuing participation of Indian pharmaceutical companies in the international generic medicines industry.

India has developed substantial manufacturing capabilities in pharmaceutical formulations and active pharmaceutical ingredients, supported by an extensive network of research organisations, manufacturing facilities and specialised service providers.

Regulatory approvals from authorities such as the USFDA enable Indian manufacturers to supply medicines to markets with demanding quality and compliance requirements.

The development of specialised formulations, including ophthalmic medicines, injectables and other complex dosage forms, has become an important area of growth for Indian pharmaceutical companies seeking to expand beyond conventional oral generic medicines.

Alembic’s collaboration with Orbicular Pharmaceutical Technologies illustrates how domestic expertise in formulation development can support international commercial opportunities.

The approval also contributes to the broader presence of Indian pharmaceutical manufacturing in global healthcare supply chains, reinforcing the industry’s role in supplying regulated markets with generic therapeutic products.

Another Milestone for India’s Pharmaceutical Export Industry

Alembic Pharmaceuticals’ final USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% marks another development in the company’s international pharmaceutical business.

The approval builds upon the tentative clearance received in December 2024 and adds an over-the-counter ophthalmic formulation to Alembic’s portfolio of USFDA-approved generic medicines.

Developed through collaboration with an Indian pharmaceutical technology company, the formulation demonstrates the capabilities of India’s pharmaceutical research and manufacturing ecosystem in meeting international regulatory requirements.

With 248 cumulative ANDA approvals, including 229 final approvals, Alembic continues to expand its regulatory portfolio in the United States. The latest clearance strengthens the company’s opportunities in ophthalmic medicines while highlighting the contribution of Indian pharmaceutical innovation and manufacturing expertise to international healthcare markets.

---